相关实验视频
Updated: Jun 14, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
118
挖掘阿尔茨海默病的临床数据:减少自然衰老的影响,以预测进展和识别亚型
Tian Han1, Yunhua Peng2,3, Ying Du4
1Systems Engineering Institute, School of Automation, Xi'an Jiaotong University, Xi'an, China.
Frontiers in neuroscience
|August 29, 2024
概括
本研究引入了张量化对比主要成分分析 (T-cPCA) 以准确预测阿尔茨海默病 (AD) 的进展和识别亚型,有效地消除自然衰老效应,以更好地提取临床数据.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 在脑缩和临床症状方面呈现出显著的异质性.
- 对阿尔茨海默病的研究面临着将疾病进展与自然衰老隔离,并提取有意义的临床数据的挑战.
研究的目的:
- 开发一种新的机器学习模型,即张力对比主要组件分析 (T-cPCA),以应对AD研究挑战.
- 预测AD的进展,并识别不同的临床亚型.
- 尽量减少自然衰老对阿尔茨海默病数据分析的影响.
主要方法:
- 利用了一个包括872个特征的综合临床变量空间,代表了当前研究中最广泛的AD特征集.
- 开发并应用了张量化对比主要组件分析 (T-cPCA) 机器学习模型.
主要成果:
- 通过有效地减轻自然衰老的影响,T-cPCA在预测AD进展方面取得了最高的准确性.
- 确定了四种主要的AD临床亚型,详细介绍了它们的代表性特征和致病电路.
- 在已识别的亚型中,斑块分布 (18F-AV45) 与临床观察和已知的AD受影响的大脑区域一致.
结论:
- T-cPCA模型为分析复杂的AD数据提供了一个强大的工具,将疾病进展与衰老分开.
- 发现不同的AD亚型为疾病机制和潜在的治疗点提供了新的见解.
- 临床验证支持模型的发现,增强对AD病变发生的理解.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.7K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
989
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107